544681-96-1

Basic information

• Product Name: 4-Isoxazolecarboxamide, N-[4-(diethylamino)phenyl]-5-methyl-3-phenyl-
• Synonyms: 3i-1000;GATA4-IN-3;GATA4-NKX2-5-IN-1;GATA4-IN-3 (GATA4 inhibitor 3);N-[4-(diethylamino)phenyl]-5-methyl-3-phenyl-4-isoxazolecarboxamide;N-[4-(Diethylamino)phenyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide
• CAS NO: 544681-96-1
• Molecular Formula: C21H23N3O2
• Molecular Weight: 349.43
• Mol File: 544681-96-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Isoxazolecarboxamide, N-[4-(diethylamino)phenyl]-5-methyl-3-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Isoxazolecarboxamide, N-[4-(diethylamino)phenyl]-5-methyl-3-phenyl-(544681-96-1)
• EPA Substance Registry System: 4-Isoxazolecarboxamide, N-[4-(diethylamino)phenyl]-5-methyl-3-phenyl-(544681-96-1)

Safety Data

• Hazardous Substances Data: 544681-96-1(Hazardous Substances Data)

Upstream product

• 1136-45-4 5-methyl-3-phenylisoxazol-4-carboxylic acid 
• 93-05-0 N,N-diethylaniline 
• 1143-82-4 ethyl 5-methyl-3-phenylisoxazole-4-carboxylate 
• 698-16-8 benzohydroximoyl chloride 

Relevant articles and documents

Discovery of Small Molecules Targeting the Synergy of Cardiac Transcription Factors GATA4 and NKX2-5

Transcription factors are pivotal regulators of gene transcription, and many diseases are associated with the deregulation of transcriptional networks. In the heart, the transcription factors GATA4 and NKX2-5 are required for cardiogenesis. GATA4 and NKX2-5 interact physically, and the activation of GATA4, in cooperation with NKX2-5, is essential for stretch-induced cardiomyocyte hypertrophy. Here, we report the identification of four small molecule families that either inhibit or enhance the GATA4-NKX2-5 transcriptional synergy. A fragment-based screening, reporter gene assay, and pharmacophore search were utilized for the small molecule screening, identification, and optimization. The compounds modulated the hypertrophic agonist-induced cardiac gene expression. The most potent hit compound, N-[4-(diethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-carboxamide (3, IC50 = 3 μM), exhibited no activity on the protein kinases involved in the regulation of GATA4 phosphorylation. The identified and chemically and biologically characterized active compound, and its derivatives may provide a novel class of small molecules for modulating heart regeneration.

ISOXAZOLE-AMIDES FOR TREATING CARDIAC DISEASES

The present invention concerns compounds of Formula 1a and its uses as a drug, particularly in treatment of cardiac diseases, and in methods and products relating to cell differentiation.

Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists

A series of isoxazole carboxamide derivatives has been developed as potent ghrelin receptor antagonists. The synthesis and structure-activity relationship (SAR) are described.